Third-quarter earnings season enters the home stretch this week. On the whole, the quarter appears to have been a mixed bag ...

Palantir stock jumped on Q3 revenue that handily beat estimates while December quarter revenue guidance came in well above expectations.

Election Day may be the biggest story of the week, but it was earnings reports driving the stock market in Tuesday morning trading. The Nasdaq Composite was up 1%, while the S&P 500 was up 0.8%. The ...

In this article, we are going to take a look at where Palantir Technologies Inc. (NYSE ... We’re about to see the same thing ...

Health care costs were very concerning to 54% of voters and somewhat ... The world will be divided between AI haves and have-nots. At Palantir, we plan to power the winners,” Palantir CEO Alexander ...

Here's Why Palantir Is My Top ... treatment and obesity care, but one clinical-stage pharma company could be the next breakout star. Ken Griffin's Citadel just added 18 million shares of an ...

Foxglove and DAUK also claim that giving the FDPP contract to Palantir will create a “monopoly lock-in” with a company that before the pandemic had “no track record in healthcare.” ...

The rally was also fuelled by a 23 per cent surge in Palantir Technologies after it signalled ... rival bank Macquarie to lead its equities research coverage of the local healthcare sector. David ...

Detailed price information for Hca Holdings Inc (HCA-N) from The Globe and Mail including charting and trades.

We upgrade Palantir stock to strong buy on strong Q3 earnings report, showing sustainable 30% YoY revenue growth and no debt.